N-Myc is overexpressed both in tumors of the nervous system such as neuroblastoma, medulloblastoma, retinoblastoma, astrocytoma, and glioblastoma multiforme, and in non-neuronal cancer characterized by castration-resistant neuroendocrine-typed prostate cancer, hematological malignancies, rhabdomyosarcoma, Wilms tumor, small-cell lung cancer, and pancreatic tumor [55, 56]. Here, MYCN is linked to prostate carcinoma.